For investors
One strain of algae.Four markets. One bet.
Algae4F turns a single, proven microalgae platform into four revenue lines: agriculture, human nutrition, skincare, and animal feed. One R&D and production engine, four shelves. This page walks you from the basics to the thesis.
The basics, in ninety seconds.
We don't sell algae. We sell its signal.
As algae grow, they make bioactive and signaling compounds called metabolites. The market sells the biomass. We capture the metabolites, the active message, and leave the biomass behind.
One source, four markets.
That single captured source is refined into four market-ready products: a soil biostimulant, a human supplement, a skincare active, and an animal-feed nutrient. Same science, four shelves.
Grown in a controlled system.
Characterized Chlorella strains grow in closed-loop vertical photobioreactors, then gentle low-temperature capture pulls out the active. Consistent, traceable, pharmaceutical-grade.
Proven, then relaunched.
The technology and the trial data are established over 20+ years. Algae4F is the clean, consolidated relaunch built to commercialize it across all four markets at once.
Four markets, one platform, multiple tailwinds.
Each vertical is a large market shifting toward exactly what the platform makes: biological, science-backed, clean-label inputs. And the farm is only the first.
$2.5B
Agriculture biologicals, growing about 12% a year. Wedge: Iron Deficiency Chlorosis affects 30% of the world's 1.65B hectares of farmland.
$3.2B
Addressable poultry market (broilers and layers), riding the global move away from antibiotic growth promoters.
Multi-billion
Global supplements and functional nutrition, where clean, bioavailable, single-source actives command a premium.
Multi-billion
Premium skincare and regenerative actives (PDRN), a fast-growing category we supply as both a finished line and a B2B ingredient.
And that is just the Farm. Food, Face, and Feed each open their own market from the same source.
Why this is hard to copy.
Signal, not biomass
Capturing the metabolite signal, rather than selling crude algae, is the core IP and the reason the product works across four very different markets.
Closed-loop vPBR
Vertical photobioreactors run 66% more productive than open ponds, contamination-free and consistent, which is what makes a pharmaceutical-grade, multi-market supply possible.
Vegan PDRN
We isolate PDRN, the prized regenerative DNA fragment, from chlorella instead of salmon: 100% vegan, renewable, and free of the ocean-pollution and animal-virus risks of the legacy supply chain.
One engine, four lines
A single cultivation and capture system feeds four products. R&D and production costs are amortized across four revenue streams, not one.
Twenty years of science. In the ground and in animals.
The platform draws on more than 20 years of commercializing high-value biological products. The core extraction was perfected at the originating lab in Sacheon, Korea, and human-grade product is now made under cGMP in Houston, Texas, including a 50-ton advanced cultivation plant on the proprietary vPBR system. New lines are in build-out, including Japan, with university and HBCU research partnerships underway.
years commercializing biologicals
trials across US, UK, Spain, Italy
corporate partners engaged
lower CO2e vs synthetic NPK (LCA)
Composition verified by an A2LA-accredited lab. OMRI-listed for organic. A disease-challenged poultry trial stood up next to antibiotics.
Operators relaunching a proven platform.
Algae4F is founder-led, built by a team that has commercialized algae biologicals before and is now consolidating that science into one global, multi-market company. We pair Korean origin science with US cGMP manufacturing and a B2B-first commercial model.
Leadership bios and the cap table are in the data room.
The thesis in five lines.
Capital-efficient by design
One platform funds four businesses. Every dollar of R&D and production serves four markets, not one.
De-risked science
This is not a science bet. 20+ years, 50+ trials, accredited verification, and a head-to-head study against antibiotics. It is an execution and scale opportunity.
Large markets with tailwinds
Biologicals, antibiotic-free feed, clean supplements, and vegan actives are all growing and all moving toward what we make.
A defensible moat
Signal-not-biomass IP, closed-loop vPBR productivity, and vegan PDRN are difficult and expensive to replicate.
Built-in optionality
Each vertical can be sold direct, licensed, or partnered. Four shots on goal from one balance sheet.
Reviewing the opportunity?
Request the investor deck and data room, or set up an intro call. We will share the full market analysis, trial data, financials, and the round.